Ironwood Pharmaceuticals, Inc.
corporate_fare Company Profile
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for IRWD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for IRWD spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Ironwood 10-Q Corrects Q3 Operating Cash Flow to $67.4M From $130.8M
- Ironwood Beats Q3 Estimates, Lifts 2026 Revenue and EBITDA Outlook
- Ironwood Lifts 2026 Guidance Again as Q3 Revenue Reaches $133M and Adjusted EBITDA Hits $98M
- Ironwood Posts 36c Adjusted EPS for Third Quarter
- Ironwood Names Tammi Gaskins CEO; McCourt Retires After 17 Years
Financial Snapshot
Short Interest & Short Volume
9.84 days to coverFINRA reported short interest of 14,860,120 shares in IRWD as of the October 30, 2026 settlement, a 6.5% decrease from the prior period — about 9.8 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of IRWD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.